- Home
- CLRB vs CTMX Comparison
CLRB vs CTMX Comparison
Compare CLRB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- CTMX
- Stock Information
- Founded
- CLRB 2002
- CTMX 2008
- Country
- CLRB United States
- CTMX United States
- Employees
- CLRB N/A
- CTMX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- CTMX Health Care
- Exchange
- CLRB Nasdaq
- CTMX Nasdaq
- Market Cap
- CLRB 76.0M
- CTMX 89.1M
- IPO Year
- CLRB N/A
- CTMX 2015
- Fundamental
- Price
- CLRB $1.86
- CTMX $0.91
- Analyst Decision
- CLRB Strong Buy
- CTMX Buy
- Analyst Count
- CLRB 2
- CTMX 6
- Target Price
- CLRB $21.00
- CTMX $5.77
- AVG Volume (30 Days)
- CLRB 289.0K
- CTMX 1.1M
- Earning Date
- CLRB 11-18-2024
- CTMX 11-07-2024
- Dividend Yield
- CLRB N/A
- CTMX N/A
- EPS Growth
- CLRB N/A
- CTMX N/A
- EPS
- CLRB N/A
- CTMX 0.16
- Revenue
- CLRB N/A
- CTMX $126,617,000.00
- Revenue This Year
- CLRB N/A
- CTMX $11.79
- Revenue Next Year
- CLRB N/A
- CTMX N/A
- P/E Ratio
- CLRB N/A
- CTMX $5.63
- Revenue Growth
- CLRB N/A
- CTMX 33.66
- 52 Week Low
- CLRB $1.82
- CTMX $0.91
- 52 Week High
- CLRB $4.45
- CTMX $5.85
- Technical
- Relative Strength Index (RSI)
- CLRB 30.70
- CTMX 32.42
- Support Level
- CLRB $1.97
- CTMX $0.98
- Resistance Level
- CLRB $2.18
- CTMX $1.08
- Average True Range (ATR)
- CLRB 0.10
- CTMX 0.06
- MACD
- CLRB -0.01
- CTMX -0.00
- Stochastic Oscillator
- CLRB 8.11
- CTMX 0.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.